Dr Reddys Laboratories has received reaffirmation in credit rating for bank facilities aggregating Rs 2,000 crore at ICRA AA+; Stable. Powered by Capital Market - Live News

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 23 January 2025.Powered by Capital Market - Live News

Dr Reddys Laboratories has allotted 13,080 equity shares under ESOS on 19 December 2024. Powered by Capital Market - Live News

Dr Reddys Laboratories announced the launch of Toripalimab in India. Toripalimab is a New Biological Entity (NBE). It is the only immuno-oncology drug approved by various regulatory authorities around the world such as the United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). In 2023, Dr. Reddy`s entered into a license and commercialisation agreement with Shanghai Junshi Biosciences Co. Ltd for Toripalimab. Under this agreement, Dr. Reddy`s obtained exclusive rights to develop and commercialise Toripalimab in 21 countries including India, South Africa, Brazil and various countries in Latin America. Additionally, the agreement allows Dr. Reddy`s to expand the scope of the license to cover Australia, New Zealand and nine other countries.With this launch by Dr. Reddy`s, India becomes the third country in the world after China and the United States to receive access to this next generation PD-1 inhibitor. Dr. Reddy`s will market it under the brand name Zytorvi� in India.The standard of care for RM-NPC in India before Toripalimab was chemotherapy (gemcitabine and cisplatin). Toripalimab is indicated as first-line treatment of adults with metastatic or recurrent locally advanced NPC in combination with gemcitabine and cisplatin. This combination has shown a 48% reduction in risk of progression or death. Additionally, Toripalimab has also been approved as monotherapy for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy.Powered by Capital Market - Live News

Dr Reddys Laboratories has received an order dated 12 November 2024, from COFEPRIS (Comisi�n Federal para la Protecci�n Contra Riesgos Sanitarios) health department of Mexico. The drug regulatory body of Mexico (Comisi�n Federal para la Protecci�n contra Riesgos Sanitarios) has imposed a penalty of MXN 651, 420 (~Rs 27 Lakh) on the Company for deviation from prescribed guidelinesin filing intimation of import of a reference standard for one of the company`s APIs. Additionally, the fine was imposed due to an error in the date of the invoice and also name of the reference standard Vs import license. Powered by Capital Market - Live News